At present, some studies have used the changes of the immune system of asthma patients as new targets (such as IgE, IL‐4, IL‐5, etc.)to generate new biological agents, but the cost‐effectiveness still needs to be considered (Conti et al. 2002; Demopoulos, Antonopoulou, and Theoharides 2020). The gene discussed is IL4; the disease is asthma.